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Aim To evaluate predictors of asymptomatic atrial fibrilla-
tion in patients older than 70 years with complete atrio-
ventricular (AV) block, normal left ventricular systolic func-
tion, and implanted dual chamber (DDD) pacemaker.
Methods Hundred and eighty six patients with complete 
AV block were admitted over one year to the Sisters of Mer-
cy University Hospital. The study recruited patients older 
than 70 years, with no history of atrial fibrillation, heart fail-
ure, or reduced left ventricular systolic function. All the pa-
tients were implanted with the same pacemaker. Out of 
103 patients who were eligible for the study, 81 (78%) were 
evaluated. Among those 81 (78%) were evaluated.
Eighty one (78%) patients were evaluated. Follow-up time 
ranged from 12 to 33 months (average ± standard devia-
tion 23 ± 5 months). Primary end-point was asymptomatic 
atrial fibrillation occurrence recorded by the pacemaker. 
Atrial fibrillation occurrence was defined as atrial high rate 
episodes (AHRE) lasting >5 minutes. Binary logistic regres-
sion was used to identify the predictors of development of 
asymptomatic atrial fibrillation.
Results The 81 patients were stratified into two groups 
depending on the presence of AHRE lasting >5 minutes 
(group 1 had AHRE>5 minutes and group 2 AHRE<5 min-
utes). AHRE lasting >5 minutes were detected in 49 (60%) 
patients after 3 months and in 53 (65%) patients after 18 
moths. After 3 months, only hypertension (odds ratio [OR], 
17.63; P = 0.020) was identified as a predictor of asymptom-
atic atrial fibrillation. After 18 months, hypertension (OR, 
14.0; P = 0.036), P wave duration >100 ms in 12 lead ECG 
(OR, 16.5; P = 0.001), and intracardial atrial electrogram sig-
nal amplitude >4 mV (OR, 4.27; P = 0.045) were identified as 
predictors of atrial fibrillation.
Conclusion In our study population, hypertension was the 
most robust and constant predictor of asymptomatic atrial 
fibrillation after 3 months, while P wave duration >100 ms 
in 12-lead ECG and intracardial atrial signal amplitude were 
predictors after 18 months.
Received: October 5, 2010
Accepted: February 2, 2011
Correspondence to: 
Nikola Pavlović 
Cardiology Department, Sisters of 
Mercy University Hospital Center 
Vinogradska cesta 29 
10000 Zagreb, Croatia 
nikolap12@yahoo.com
Vjekoslav Radeljić, Nikola 
Pavlović, Šime Manola, 
Diana Delić-Brkljačić, 
Hrvoje Pintarić, Dubravko 
Petrač
Department of Cardiology, Sisters 
of Mercy University Hospital, 
Zagreb, Croatia
Incidence and predictors of 
asymptomatic atrial fibrillation 
in patients older than 70 years 
with complete atrioventricular 




doi: 10.3325/cmj.2011.52.61CLINICAL SCIENCES 62 Croat Med J. 2011; 52: 61-7
www.cmj.hr
Atrial fibrillation is the most common cardiac arrhythmia, 
which is associated with high morbidity and mortality, 
primarily due to cerebrovascular thromboembolic acci-
dents and heart failure (1). Atrial fibrillation can be either 
symptomatic or asymptomatic. The incidence and prev-
alence of asymptomatic atrial fibrillation in the general 
population and in patients who have a dual chamber per-
manent pacemaker (PPM) is unknown. Previous studies 
have shown that 90% of the patients with an implanted 
dual chamber PPM and previously documented atrial fi-
brillation are asymptomatic since they lack irregular ven-
tricular rate (2).
It is well known that age is an important risk factor for the 
development of atrial fibrillation (3,4). It is also known that 
the majority of elderly people with atrial fibrillation die of 
stroke or heart failure (5).
Given the assumption that asymptomatic atrial fibrillation 
can contribute to those events, the question is whether 
we can stratify patients according to their risk of asymp-
tomatic atrial fibrillation by using simple accessible meth-
ods. The first estimates of the asymptomatic atrial fibril-
lation incidence were published in 1994 and reported a 
ratio  of  asymptomatic  to  symptomatic  atrial  fibrillation 
of  about  12:1  (3,6).  Studies  investigating  patients  with 
stroke or transient ischemic attack found atrial fibrillation 
in about 15%-28% of patients, depending on the moni-
toring method used, and excluding those with previously 
known atrial fibrillation (7,8).
The Atrial Fibrillation Follow-up Investigation of Rhythm 
Management study, which compared the rate vs rhythm 
control  in  participants  with  atrial  fibrillation  older  than 
65 years, showed a trend toward higher mortality in the 
rhythm control arm. Stroke as significant contributor to 
mortality in this group was explained by warfarin with-
drawal and asymptomatic atrial fibrillation occurrence (9).
Comparative advantage of patients with implanted pace-
maker is that they are under rhythm monitoring perma-
nently, thus leading to detection of asymptomatic atrial 
fibrillation (10). In this study, we proposed that analyzing 
12-lead  ECG,  natriuretic  peptide  values,  and  pacemaker 
recordings can help to identify patients who are at high-
er risk of developing asymptomatic atrial fibrillation and 
complications of this arrhythmia. The aim of this study is 
to evaluate the predictors of asymptomatic atrial fibril-
lation in patients with complete atrioventricular (AV) 
block and implanted PPM.
PatieNts aND MetHoDs
Patients
A total of 186 consecutive patients with complete AV block 
were admitted to the Department of Cardiology at the Sis-
ters of Mercy University Hospital in Zagreb, Croatia be-
tween September 1, 2005 and September 1, 2006. Overall, 
103 patients were older than 70 years (77 years, range 71-
94 years) and thus eligible for the participation in the study. 
Table 1 shows the demographic data of the patients. Of 
the total 103 patients, 13 refused to participate and 9 were 
lost to follow-up.
Inclusion criteria for this prospective study were complete 
AV block, age older than 70 years, and dual chamber PPM. 
Exclusion criteria were history of atrial fibrillation, previous 
heart surgery, systolic and diastolic heart failure, hyper-
thyroidism, reduced left ventricular systolic function esti-
mated using left ventricular ejection fraction <50%, mea-
sured by Simpson (11) and Teichholz method (12), mitral 
stenosis of any degree, left atrial dilatation (greater than 50 
mm measured from the parasternal long axis), moderate 
or severe mitral regurgitation, and renal failure. A signed 
informed consent for permanent pacemaker implantation 
and for the participation in the study was obtained. The 
study was approved by Ethics Committees of the hospital 
and the Zagreb University Medical School.
MetHoDs
The study included patients with complete AV block who 
received PPM. Indications for permanent pacemaker im-
plantation were made according to the ACC/AHA/NASPE 
2002 Guideline Update for Implantation of Cardiac Pace-
makers and Antiarrhythmia Devices (13). All patients had 
a dual chamber PPM (SIGMA 303 DDDR, Medtronic, Min-
neapolis, MN, USA) implanted using cephalic or subclavi-
an approach on the non-dominant hand side. Atrial lead 
was implanted in the right atrial appendage and ventricu-
lar lead in the right ventricular apex using active fixation 
leads. In all patients, pacemaker was programmed in DDDR 
mode with the same lower rate of 60 bpm, without any ar-
rhythmic interventional algorithm available.
Several variables were considered as potential predictors 
of atrial fibrillation. Some of them are already known risk 
factors, such as age, diabetes, hypertension, and left atrium 
diameter (4). In addition, we wanted to test the associa-
tion of the following factors with the atrial fibrillation: atrial 63 Radeljić et al: Asymptomatic atrial fibrillation in elderly patients
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electrogram characteristics, brain natriuretic peptides con-
centrations, and cumulative pacing rate. Parameters eval-
uated were P wavelength, sex, age, arterial hypertension, 
diabetes  mellitus,  angiotensin-converting  enzyme  (ACE) 
inhibitors,  beta  blockers,  left  atrium  diameter  in  systole 
(measured in parasternal long axis – PLAX), diastolic dys-
function (grade II or higher), intracardiac atrial signal ampli-
tude >4 mV and width >50 ms, cumulative ventricular pac-
ing >70%, cumulative dual chamber pacing >20%, B-type 
natriuretic peptide (BNP), atrial natriuretic peptide (ANP), 
body mass index, and QRS width. We defined asymptom-
atic atrial fibrillation as atrial high rate episodes (AHRE) de-
tected by the pacemaker, lasting for more than 5 minutes, 
as described in previous studies (14). In all study patients, 
the atrial bipolar sensitivity was programmed to 0.5 mV, 
and the AHRE diagnostic was programmed ON (with cut-
off rate at 180bpm).
Clinical evaluation and blood sampling
During the hospital stay, a complete medical history and 
physical examination were obtained for every patient. Stan-
dard 12-lead ECG, chest x-ray before and after PPM implan-
tation,  echocardiography,  and  standard  laboratory  tests 
were also performed. Blood (complete blood count, blood 
urea nitrogen, creatinine, electrolytes, glucose, creatine ki-
nase, lactate dehydrogenase, troponin T levels, prothrom-
bin time and activated partial thromboplastin time, C reac-
tive protein, acid-base status, lipid profile) and urine were 
sampled for routine analysis and the tests were performed 
by the central hospital laboratory. Blood pressure was mea-
sured each day during the hospital stay and then at each 
follow-up visit. Blood pressure was measured according to 
the Practice Guidelines of the European Society of Hyper-
tension for clinic, ambulatory, and self blood pressure mea-
surement and the 2003 European Society of Hypertension 
– European Society of Cardiology guidelines for the man-
agement of arterial hypertension (15,16). Blood pressure 
was measured using mercury sphyngomanometer on both 
arms with the patient sitting, with back support, legs un-
crossed, and the arm supported at heart level. Hyperten-
sion was defined as blood pressure higher than 140/90 
mm Hg measured two times at least 24 hours apart (16). 
All patients were instructed about possible atrial fi-
taBle 1. Key characteristics of 81 patients with atrial fibrillation included in the study on incidence and predictors in patients older 
than 70 y with complete atrioventricular block and dual chamber pacemaker implantation*†
No. (%) of patients with asymptomatic atrial fibrillation at:
3 mo 18 mo
Patient characteristic baseline yes (n = 49) no (n = 32) yes (n = 53) no (n = 28)
Male sex   53 (65)   34 (69)   19 (59)   37 (70)   16 (57)
Body mass index (mean ± standard deviation)   25.6 ± 1.9   25.7 ± 1.8   25.6 ± 2   25.6 ± 1.9   25.7 ± 1.2
Comorbidities:
hypertension   71 (88)   45 (92)   26 (81)   49 (93)   22 (79)
diabetes mellitus   16 (20)   10 (20)     6 (19)     4 (8)     6 (21)
eCG (mean ± standard deviation):
QRS width (ms) 105 ± 32 105 ± 3 106 ± 31 108 ± 3 102 ± 33
P wave width (ms)   99 ± 25 104 ± 3†   92 ± 19 106 ± 3†   85 ± 15
echocardiographic parameters:
LVEF>50%   81 (100)   49 (100)   32 (100)   53 (100)   28 (100)
diastolic dysfunction   22 (27)   14 (29)     8 (25)   16 (30)     6 (21)
interventricular septum (mm in diastole), mean ± standard deviation   12.7 ± 4.7   13.1 ± 5.5   12.2 ± 2.9   13 ± 5.4   12.2 ± 3
left atrium (mm, PLAX in systole), mean ± standard deviation   42.3 ± 3.7   42 ± 4.3   42.7 ± 2.8   42.2 ± 4   42.4 ± 3.3
left ventricle (mm, PLAX in diastole), mean ± standard deviation   51.1 ± 4.3   51.8 ± 4.7   49.9 ± 3.2   51.6 ± 4.9   50.1 ± 2.6
B type natriuretic peptide (mean ± standard deviation)   63.5 ± 73.9   56.5 ± 63.1   66.9 ± 83   53.2 ± 84.3
atrial natriuretic peptide (mean ± standard deviation)   34.8 ± 18.6   38.9 ± 17.7   37.1 ± 22.4   35.2 ± 17.4
therapy:
beta blockers   12 (25)   10 (31)   14 (26)     8 (29)
ACE inhibitors   35 (71)   23 (71.9)   39 (73.6)   19 (68)
ventricular pacing >70% of time   38 (78)   21 (66)   40 (76)   19 (68)
*abbreviations: lVeF – left ventricular ejection fraction; PlaX – parasternal long axis.
†P < 0.05 vs no asymptomatic atrial fibrillation (independent samples t test).CLINICAL SCIENCES 64 Croat Med J. 2011; 52: 61-7
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brillation symptoms before discharge from the hospital and 
were asked to keep a log of their symptoms.
Follow-up
Patients were followed-up in the outpatient clinic every 
three months. On each of the visits, standard physical sta-
tus was obtained with blood pressure measurement as 
well as 12-lead ECG recording (ECG was recorded at stan-
dard 25 mm/s speed as well as 50 mm/s for more accurate 
measurements of P and R wave duration) and pacemak-
er interrogation (Medtronic CareLink programmer, model 
nr. 2090). Electrocardiographic parameters (P and R wave) 
were evaluated by a single observer on standard 12-chan-
nel ECG with 50 mm/s speed of recording (a median value 
of 3 consecutive beats was taken), and intracardiac mea-
surements were performed during the pacemaker exami-
nation (atrial intracardiac electrogram duration and ampli-
tude in unipolar and bipolar mode, taking a median value 
of  3  consecutive  beats).  Atrial  sensing  was  adjusted  as 
30% to measured P wave amplitude with the intention to 
avoid atrial over-sensing and under-sensing. Patients were 
both interviewed and given a short questionnaire regard-
ing symptoms. Blood was collected for atrial and brain na-
triuretic peptides. The upper limit of normal for BNP was 
<18.4 pg/mL and for ANP was <43 pg/mL according to 
manufacturer’s  recommendations.  Both  concentrations 
were determined by an immunoradiometric assay (SHION-
ORIA ANP and SHIONORIA BNP in vitro test; CIS Bio Interna-
tional, Gif-Sur-Yvette, Cedex, France).
statistical analysis
Distribution  of  values  of  individual  variables  was  deter-
mined  using  Kolmogorov-Smirnov  test  and  appropriate 
parametric and nonparametric tests were applied for the 
further analysis. Chi -square test was used to test the dif-
ferences in qualitative variables between the groups. In-
dependent samples t test was used as univariate method 
to assess the differences in the quantitative variables (age, 
body mass index, QRS, and P wave width, IVS, left atrium, 
left ventricle, BNP, ANP) between symptomatic and asymp-
tomatic groups. To estimate the influence of clinical and 
other factors on the development of asymptomatic atri-
al  fibrillation,  binary  logistic  regression  was  conducted. 
P < 0.05 was considered to be significant. Software Statis-
tica V8.0 (StatSoft, Inc., Tulsa, OK, USA) was used for the 
analysis.
Results
The 81 patients who were eligible for this study underwent 
pacemaker  implantation  and  were  subsequently  moni-
tored over 12 to 33 months (average and standard devi-
ation: 23 ± 5 months) and stratified into two groups de-
pending on the duration of AHRE. The average age of the 
patients was 81 ± 6 years, 53 were male (65%), 71 (88%) had 
a history of hypertension, and 16 (20%) had a history of 
diabetes (baseline data summarized in Table 1). All patients 
had left ventricular ejection fraction ≥50%. After 3 months, 
49 (60%) patients had AHRE, while the remaining 32 (40%) 
had no AHRE (Table 1). After 18 months, AHRE lasting for 
more than 5 minutes were detected in additional 4 pa-
tients so that 53 (65%) patients developed asymptomatic 
atrial fibrillation (Table 1). Univariate analysis showed that 
the only significant difference between the two groups 
was detected for native P wave duration >100 ms (P = 0.023 
after 3 months and P < 0.001 after 18 months).
taBle 2. Predictors of asymptomatic atrial fibrillation occur-
rence in patients (n = 81) included in the study on incidence 
and predictors in patients older than 70 y with complete 
atrioventricular block and dual chamber pacemaker implanta-
tion at 3 and 18 mo follow-up. 
Follow up, odds ratios 
(95% confidence intervals)
Monitored parameter 3 mo 18 mo
P wave width ≥100 ms   1.90 (0.55-6.50) 16.51(2.97-1.69)†
Age   1.00 (0.93-1.07)   1.03 (0.96-1.11)
Male sex   2.11 (0.69-6.49)   2.05 (0.57-7.45)
Arterial hypertension 17.63 (1.57-197.84)* 14.00 (1.19-165.43)†
Diabetes mellitus   1.15 (0.24-5.54)   2.04 (0.40-10.29)
ACE inhibitors   0.22 (0.03-1.46)   0.22 (0.03-1.69)
Beta blockers   0.75 (0.21-2.65)   1.03 (0.23-4.58)
LA diameter in systole 
(PLAX)
  0.90 (0.77-1.07)   0.91 (0.76-1.08)
Diastolic dysfunction 
(grade II or more)
  0.50 (0.12-2.08)   0.90 (0.17-4.65)
Intracardiac atrial signal 
amplitude >4 mV
  0.63 (0.18-2.22)   4.27 (1.03-17.70)
Intracardiac atrial signal 
width >50 ms
  1.00 (0.20-5.08)   3.17 (0.45-22.08)
Cumulative ventricular 
pacing >70%
  0.40 (0.08-1.95)   0.72 (0.009-5.72)
Cumulative dual chamber 
pacing >20%
  0.26 (0.04-1.79)   0.40 (0.08-1.95)
B type natriuretic peptide   1.01 (1.00-1.02)   1.00 (0.99-1.01)
Atrial natriuretic peptide   0.96 (0.93-1.00)*   0.99 (0.95-1.02)
Body mass index   1.04 (0.79-1.37)   0.90 (0.65-1.25)
QRS width   1.00 (0.98-1.02)   0.99 (0.97-1.02)
*abbreviations: la – left atrium; PlaX – parasternal long axis.
†P < 0.05 vs no atrial fibrillation (binary logistic regression).65 Radeljić et al: Asymptomatic atrial fibrillation in elderly patients
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The multivariate analysis performed by binary logistic re-
gression (Table 2) showed that the only significant pre-
dictor of developing atrial fibrillation after 3 months was 
arterial hypertension (odds ratio [OR], 17.63; 95% confi-
dence interval [CI], 1.57-197.54) (Cox and Snell R2 = 31%, 
Nagelkerke  R2 = 43%). The  analysis  of  the  18-month  fol-
low-up identified 3 predictors of atrial fibrillation: arterial 
hypertension (OR, 14.0;95% CI, 1.19-163.45), P wave width 
greater than 100 ms in the standard 12-lead ECG (OR, 16.5; 
95% CI, 2.97-91.69), and amplitude of intracardiac atrial po-
tential >4 mV (OR, 4.27; 95% CI, 1.03-17.70) (Cox and Snell 
R2 = 20%, Nagelkerke R2 = 27%).
DisCussioN
We found that the incidence of asymptomatic atrial fibril-
lation (defined as AHRE lasting more than 5 minutes) was 
65%. The multivariate analysis showed that the strongest 
predictor of asymptomatic atrial fibrillation in the patients 
with complete AV block and implanted permanent pace-
maker was arterial hypertension. Low R2 values in logistic 
regression are the norm and this presents a problem when 
reporting their values to an audience accustomed to see-
ing linear regression values. Although some authors do not 
recommend routine publishing of R2 values from fitted lo-
gistic regression models, there are different opinions be-
cause higher percentage of explained variance is strongly 
connected to the number of predictors used in the model 
(17). It is much more important to know what we measure 
rather than to have the range of R2 values similar to those 
of linear regression (18). Other predictors of atrial fibrilla-
tion after 18 months were P wave width measured on stan-
dard ECG and intracardiac atrial signal amplitude.
Previous studies have shown an even greater incidence of 
atrial arrhythmias in patients with implanted pacemakers. 
The A-HIRATE study showed that the incidence of AHRE 
was 89% in patients with previous atrial tachyarrhythmias 
and 49% in patients with no history of atrial tachyarrhyth-
mias (19). Quirino et al (20) showed that the incidence of 
atrial fibrillation was 74%. Both of these studies showed 
that most of the episodes were asymptomatic. Quirino et 
al also showed low sensitivity and positive predictive value 
of symptoms in detecting atrial fibrillation with dual cham-
ber pacemakers, although this study investigated different 
group of patients (sick sinus syndrome).
According to previous reports, and European Society of 
Cardiology Guidelines for the management of atrial fibril-
lation, implantable devices can detect atrial fibrillation ap-
propriately, particularly when the cut-off point for duration 
of AHRE>5 minutes are used (8,21). Also, as it was reported 
in the A-HIRATE study, pacemaker diagnostic algorithms 
showed high sensitivity and specificity, as well as positive 
predictive value for atrial tachyarrhythmias (19).
Our study shows a relatively high incidence of asymptom-
atic atrial fibrillation. Since all our patients were over 70 
years old, 88% of them had arterial hypertension, and 20% 
had diabetes, the risk of stroke for those with proven atrial 
fibrillation is high.
Bearing in mind that the predictive value of pacing diag-
nostics for atrial fibrillation is high and that previous stud-
ies showed low sensitivity and positive predictive value of 
the symptoms to detect atrial fibrillation (20), our study in-
dicates that when AHRE are found in a high risk population 
oral anticoagulation should be considered as a treatment 
option.
In contrast to some studies that suggested ACE inhibitors 
as effective non-antiarrhytmic drugs in preventing atrial fi-
brillation, our study failed to prove their influence on atrial 
fibrillation (22). In our study, hypertension was identified 
as the strongest predictor of atrial fibrillation. Although hy-
pertension is not the strongest predictor of atrial fibrilla-
tion in general population, it is the most common under-
lying disease in patients with atrial fibrillation (23,24). Also, 
we measured cumulative ventricular (>70%) and cumula-
tive dual chamber pacing (>20%). Both of these parame-
ters did not increase the risk of asymptomatic atrial fibril-
lation although one would expect it. Possible explanation 
for these findings is the small number of patients and a 
relatively short follow-up. Moreover, we included very ho-
mogenous group of patients with no signs of heart failure, 
which could have introduced bias into our results.
Another predictor of atrial fibrillation in our study was P 
wave  width  measured  on  standard  ECG.  Different  elec-
trocardiographic  markers  have  been  proposed  for  the 
assessment of risk for atrial fibrillation: maximum P wave 
duration, P index, P wave dispersion, and morphological 
changes of the P waves (25-28). Although none of these 
was clearly conclusive in our study population, P wave 
width appeared as potential predictor of atrial fibrillation 
after 18 months. We find this result particularly important 
since this parameter is far more available than signal aver-
age P wave duration proposed by other authors (29). In 
addition, P wave duration is generally accepted as reli-
able non-invasive marker of atrial conduction and its CLINICAL SCIENCES 66 Croat Med J. 2011; 52: 61-7
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prolongation has been associated with the history of atrial 
fibrillation. Furthermore, P wave duration was previously 
reported as a predictor of atrial fibrillation occurrence after 
cardiac surgery and predictor of transition from paroxys-
mal to permanent atrial fibrillation (25,26).
We also found that P wave ampitude >4 mV on intracar-
diac recording could serve as a predictor of asymptomatic 
atrial fibrillation in patients after 18 months. This could par-
tially be explained by the fact that patients with better atri-
al lead sensing and higher P wave amplitudes could have 
better detection of atrial arrhythmias.
Some  other  characteristics  that  could  be  expected  to 
have an effect on atrial fibrillation occurrence, such as 
cumulative ventricular or cumulative dual chamber pac-
ing rate, BNP and ANP levels, were not associated with as-
ymptomatic atrial fibrillation occurrence in our study. This 
is probably due to a relatively small number of patients. 
As previously discussed, this study analyzed very homog-
enous group of patients and thus the results cannot be 
applied to patients with other indications for permanent 
cardiac pacing. Other conditions, such as heart failure or 
severe mitral regurgitation, can be stronger predictors of 
atrial fibrillation but those patients were not included in 
our study.
In conclusion, we showed that hypertension was the most 
robust and constant predictor of asymptomatic atrial fi-
brillation occurrence, while P wave duration >100 ms in 
12-lead ECG and intracardial atrial signal amplitude could 
serve as predictors after 18 months. High incidence of as-
ymptomatic atrial fibrillation mandates close and careful 
follow-up of patients with PPM, and in patients with high 
risk the utilization of oral anticoagulation should be con-
sidered. Future prospective studies on larger number of 
patients are needed to confirm and support our findings.
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